LFM-A13

• Description:

  LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

• UNSPSC:

  12352200

• Hazard Statement:

  H302+H312+H332, H315, H319

• Target:

  Btk; JAK; Polo-like Kinase (PLK)

• Type:

  Biochemical Assay Reagents

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lfm-a13-1.html

• Purity:

  99.65

• Solubility:

  10 mM in DMSO

• Smiles:

  C/C(O)=C(C#N)/C(NC1=CC(Br)=CC=C1Br)=O

• Molecular Formula:

  C11H8Br2N2O2

• Molecular Weight:

  360.00

• Precautions:

  H302+H312+H332, H315, H319

• References & Citations:

  [1]Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N- (2, 5-dibromophenyl) propenamide]. J Biol Chem. 1999 Apr 2;274 (14) :9587-99.|[2] van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385 (5) :409-13.|[3]Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK) . Bioorg Med Chem. 2007 Jan 15;15 (2) :800-14.|[4]Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2018 Jun;36 (3) :388-395.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Biochemical Assay Reagents

• Clinical Information:

  No Development Reported

• Isoform:

  PLK1; PLK3

• CAS Number:

  [62004-35-7]